Waking repeatedly to urinate or managing a diagnosis of diabetes insipidus can be disruptive to daily life. Desmopressin is a long-established synthetic therapy designed to address both concerns by replacing a hormone the body may not produce or use effectively.
Key takeaways
- Desmopressin acetate is approved as antidiuretic replacement therapy for central diabetes insipidus.
- It is also approved for managing temporary polyuria and polydipsia after head trauma or pituitary surgery.
- Desmopressin acetate tablets are indicated for primary nocturnal enuresis.
- The compound does not work for nephrogenic diabetes insipidus.
- More than 150 registered clinical trials have studied desmopressin across various conditions.
What Desmopressin Is
Desmopressin is marketed under the brand name Desmopressin Acetate. It is used as an antidiuretic replacement, meaning it substitutes for a hormone involved in regulating how much water the kidneys retain or release.
What Desmopressin Is Approved For
Desmopressin acetate tablets are indicated for central diabetes insipidus, where they serve as antidiuretic replacement therapy. They are also approved for the temporary polyuria and polydipsia that can follow head trauma or surgery in the pituitary region. Diagnosis for these uses typically relies on the water deprivation test, the hypertonic saline infusion test, or response to antidiuretic hormone, and ongoing response can be tracked through urine volume and osmolality. Separately, desmopressin acetate tablets are indicated for primary nocturnal enuresis. The label notes that desmopressin acetate is not effective for nephrogenic diabetes insipidus, a different underlying cause of excess urination.
What the Evidence Shows
Desmopressin has been studied in 156 registered clinical trials. A completed phase 3 trial evaluated a desmopressin melt formulation for treating nocturia, and another completed phase 3 study assessed long-term safety in patients with nocturia. A separate phase 3 trial examining desmopressin's role in reversing trauma-induced coagulopathy was terminated.
Reported Side Effects
Reported adverse event data reflect submitted reports, not confirmed incidence or causation. The most frequently reported reaction is hyponatraemia, with 357 reports, reflecting the drug's effect on water and sodium balance. Neurological and general symptoms follow, including headache (268 reports), fatigue (173), and dizziness (139). Gastrointestinal reports include nausea (205) and vomiting (154). Reports of drug ineffectiveness (258) and off-label use (146) were also common in the data.